These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15561823)

  • 21. Synthesis of 6-acetamido-5-amino- and -5-guanidino-3, 4-dehydro-N-(2-ethylbutyryl)- 3-piperidinecarboxylic acids related to zanamivir and oseltamivir, inhibitors of influenza virus neuraminidases.
    Shitara E; Nishimura Y; Nerome K; Hiramoto Y; Takeuchi T
    Org Lett; 2000 Nov; 2(24):3837-40. PubMed ID: 11101432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
    Gubareva LV; Penn CR; Webster RG
    Virology; 1995 Oct; 212(2):323-30. PubMed ID: 7571401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
    Govorkova EA; Fang HB; Tan M; Webster RG
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
    Yen HL; Herlocher LM; Hoffmann E; Matrosovich MN; Monto AS; Webster RG; Govorkova EA
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4075-84. PubMed ID: 16189083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design of potent sialidase-based inhibitors of influenza virus replication.
    von Itzstein M; Wu WY; Kok GB; Pegg MS; Dyason JC; Jin B; Van Phan T; Smythe ML; White HF; Oliver SW
    Nature; 1993 Jun; 363(6428):418-23. PubMed ID: 8502295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
    Aoki FY; Hayden FG
    Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
    [No Abstract]   [Full Text] [Related]  

  • 27. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
    Honda T; Yoshida S; Arai M; Masuda T; Yamashita M
    Bioorg Med Chem Lett; 2002 Aug; 12(15):1929-32. PubMed ID: 12113811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
    Barnett JM; Cadman A; Gor D; Dempsey M; Walters M; Candlin A; Tisdale M; Morley PJ; Owens IJ; Fenton RJ; Lewis AP; Claas EC; Rimmelzwaan GF; De Groot R; Osterhaus AD
    Antimicrob Agents Chemother; 2000 Jan; 44(1):78-87. PubMed ID: 10602727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disarming flu viruses.
    Laver WG; Bischofberger N; Webster RG
    Sci Am; 1999 Jan; 280(1):78-87. PubMed ID: 9891421
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir.
    Honda T; Masuda T; Yoshida S; Arai M; Kaneko S; Yamashita M
    Bioorg Med Chem Lett; 2002 Aug; 12(15):1925-8. PubMed ID: 12113810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance of influenza viruses to neuraminidase inhibitors--a review.
    McKimm-Breschkin JL
    Antiviral Res; 2000 Jul; 47(1):1-17. PubMed ID: 10930642
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
    Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
    Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zanamivir: from drug design to the clinic.
    Elliott M
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor.
    von Itzstein M; Wu WY; Jin B
    Carbohydr Res; 1994 Jun; 259(2):301-5. PubMed ID: 8050102
    [No Abstract]   [Full Text] [Related]  

  • 35. The low potential for drug interactions with zanamivir.
    Daniel MJ; Barnett JM; Pearson BA
    Clin Pharmacokinet; 1999; 36 Suppl 1():41-50. PubMed ID: 10429839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuraminidase inhibitors as antivirals.
    Colman PM
    Vaccine; 2002 May; 20 Suppl 2():S55-8. PubMed ID: 12110259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
    Thompson CI; Barclay WS; Zambon MC
    J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
    Kim JH; Resende R; Wennekes T; Chen HM; Bance N; Buchini S; Watts AG; Pilling P; Streltsov VA; Petric M; Liggins R; Barrett S; McKimm-Breschkin JL; Niikura M; Withers SG
    Science; 2013 Apr; 340(6128):71-5. PubMed ID: 23429702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase.
    Sahasrabudhe A; Lawrence L; Epa VC; Varghese JN; Colman PM; McKimm-Breschkin JL
    Virology; 1998 Jul; 247(1):14-21. PubMed ID: 9683567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
    Kaji M
    Nihon Rinsho; 2003 Nov; 61(11):1975-9. PubMed ID: 14619441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.